TEVA250509P15000
- 0.01
- 0.000.00%
Teva Pharmaceutical Industries Newsroom
Research Alert: CFRA Maintains Sell Opinion On Shares Of Teva Pharmaceutical Industries
Express News | Form 144 | Teva Pharmaceutical Industries(TEVA.US) Officer Proposes to Sell 6.1 Million in Common Stocks
Teva Pharmaceutical Indus Analyst Ratings
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $22
Express News | Teva : BofA Global Research Raises Price Objective to $22 From $20
Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday
10-Q: Q1 2025 Earnings Report
Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
Teva Targets $2.5B Sales for Austedo in 2027 While Advancing Innovative Portfolio
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say
Sector Update: Health Care Stocks Advance Pre-Bell Wednesday
Express News | U.S.-Listed Shares of Teva Pharmaceutical Industries up 7.9% Premarket After Larger Than Expected Rise in Q1 Profit
Research Alert: Teva Reports Q1 Eps Beat With Solid Revenue Growth By Austedo
Teva Rises as Forex Impact Drives Q1 Revenue Miss
Teva Pharmaceutical's Q1 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Updated
Teva Pharmaceutical Industries Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adjusted EPS Results and Raised Its FY25 Adjusted EPS Guidance.
Express News | Teva Pharmaceutical Indus Raises FY2025 Adj EPS Guidance From $2.35-$2.65 To $2.45-$2.65 Vs $2.55 Est; Narrows FY2025 Sales Guidance From $16.80B-$17.40B To $16.80B-$17.20B Vs $17.24B Est
Teva Pharmaceuticals 1Q EPS 18c >TEVA
Teva Pharmaceutical Indus Q1 Adj. EPS $0.52 Beats $0.48 Estimate, Sales $3.89B Miss $4.00B Estimate